NMTi

NMTi, a new ADC payload toxin developed by Myricx Bio, inhibits NMT to disrupt mitochondrial function and induce endoplasmic reticulum stress, thereby killing cancer cells. Its simple structure facilitates synthesis. In preclinical studies, it exhibits efficacy and safety in solid tumors; NMTi-ADCs feature dual targeting and strong bystander activity, and outperform T-Dxd in some models.